两种四联疗法根除幽门螺旋杆菌的临床效果观察
详细信息 查看官网全文
- 论文作者：刘薇薇 ; 徐岩
- 年：2016
- 作者机构：北京市西城区德胜社区卫生服务中心;北京大学临床研究所;
- 论文关键词：四联疗法 ; 阿莫西林 ; 克拉霉素 ; 幽门螺旋杆菌 ; 效果
- 英文论文关键词：quadruple therapy ; Amoxicillin ; Clarithromycin ; Helicobacter pylori ; The effect
- 会议召开时间：2016-11-25
- 会议录名称：湖南中医药大学学报2016/专集：国际数字医学会数字中医药分会成立大会暨首届数字中医药学术交流会论文集
- 语种：中文
- 分类号：R573.1
- 学会代码：HNZY
- 会议名称：国际数字医学会数字中医药分会成立大会暨首届数字中医药学术交流会
- 会议地点：中国广东珠海
- 主办单位：国际数字医学会、Digital Chinese Medicine
- 学会名称：湖南中医药大学期刊杂志社
- 页数：1
- 文件大小：2015k
- 原文格式：D
- 会议级别：全国
摘要
目的:探讨2种四联疗法根除幽门螺旋杆菌的临床效果。方法:选取2015年8月至2016年1月来我社区服务站就诊有消化道症状的患者,筛选幽门螺旋杆菌阳性并有治疗适应症的80例患者为研究对象,随机分为A组和B组,每组各40人,分别进行四联疗法A组(奥美拉唑+复方铝酸铋+克拉霉素+甲硝唑)和四联疗法B组(埃索美拉唑+枸橼酸铋钾+甲硝唑+阿莫西林)治疗幽门螺旋杆菌阳性患者,疗程14天,停药四周后复查13C-尿素呼气试验,对两组根除效果、临床症状缓解有效率、药物不良反应情况进行比较。结果:B组Hp的根除率(95%)显著高于A组(82.5%),(p<0.05);B组临床症状缓解有效率(92.5%)与A组(90%)无明显差异(p>0.05);B组药物不良反应与A组无明显差异(P>0.05)。结论:埃索美拉唑+枸橼酸铋钾+甲硝唑+阿莫西林的四联疗法对幽门螺旋杆菌的根除效果明显优于奥美拉唑+复方铝酸铋+克拉霉素+甲硝唑的四联疗法,两组临床疗效无明显差异,两组药物副作用差异不大,均未出现严重的药物不良反应,社区治疗幽门螺旋杆菌阳性患者可考虑患者综合因素选择合适的根除方案。
Objective: To study the two kinds of quadruple therapy clinical effect of eradication of helicobacter pylori. Methods: choose between August 2015 and January 2015 to my communityservice station clinic patients with gastrointestinal symptoms, screening of h. pylori positive indications and treatment of 80 patients as the research object, were randomly divided into group A and group B, each group 40 people, respectively to quadruple therapy group A(omeprazole + compound bismuth aluminate, clarithromycin and metronidazole) and quadruple therapy group B(esso beauty pullazole + k + metronidazole, amoxicillin bismuth citrate) in the treatment of helicobacter pylori positive patients, treatment for 14 days, four weeks after stopping drug review- 13 C urea breath test, tothe eradication of the two groups effect, clinical symptoms effectively, comparing the situation of adverse drug reactions. Results: in group B Hp eradicate rate(95%) were significantly higher in group A(82.5%),(p < 0. 05); Clinical curative effect(92.5%) and group B(90%) in group A, there was no significant difference(p > 0. 05), group B drug adverse reaction and no obvious difference was foundbetween group A(p > 0.05). Conclusion: esso beauty pull azole + bismuth potassium citrate + metronidazole, amoxicillin quadruple therapy for helicobacter pylori eradication effect is obviously betterthan that of omeprazole + compound bismuth aluminate, clarithromycin and metronidazole quadruple therapy, no difference between the two groups of clinical curative effect, these two groups of drugside effects, no serious adverse drug reactions occurred in the treatment of helicobacter pylori patients in community can choose appropriate considering comprehensive factors in patients with eradicationprogram.
Objective: To study the two kinds of quadruple therapy clinical effect of eradication of helicobacter pylori. Methods: choose between August 2015 and January 2015 to my communityservice station clinic patients with gastrointestinal symptoms, screening of h. pylori positive indications and treatment of 80 patients as the research object, were randomly divided into group A and group B, each group 40 people, respectively to quadruple therapy group A(omeprazole + compound bismuth aluminate, clarithromycin and metronidazole) and quadruple therapy group B(esso beauty pullazole + k + metronidazole, amoxicillin bismuth citrate) in the treatment of helicobacter pylori positive patients, treatment for 14 days, four weeks after stopping drug review- 13 C urea breath test, tothe eradication of the two groups effect, clinical symptoms effectively, comparing the situation of adverse drug reactions. Results: in group B Hp eradicate rate(95%) were significantly higher in group A(82.5%),(p < 0. 05); Clinical curative effect(92.5%) and group B(90%) in group A, there was no significant difference(p > 0. 05), group B drug adverse reaction and no obvious difference was foundbetween group A(p > 0.05). Conclusion: esso beauty pull azole + bismuth potassium citrate + metronidazole, amoxicillin quadruple therapy for helicobacter pylori eradication effect is obviously betterthan that of omeprazole + compound bismuth aluminate, clarithromycin and metronidazole quadruple therapy, no difference between the two groups of clinical curative effect, these two groups of drugside effects, no serious adverse drug reactions occurred in the treatment of helicobacter pylori patients in community can choose appropriate considering comprehensive factors in patients with eradicationprogram.
引文
[1]薛芙蕖.四联疗法治疗幽门螺杆菌阳性消化性溃疡疗效观察[J].中国基层医药,2011,18(19):2682-2683.
[2]于凌琪.幽门螺旋杆菌的研究进展[J].中国慢性病预防与控制,2010,02:218-219.
[3]胡伏莲.幽门螺杆菌感染与上胃肠道疾病[J].临床内科杂志,2003,02:57-59.
[4]王晶桐,林珊珊,刘玉兰等.不同方案根除幽门螺旋杆菌效果对比分析[J]中国综合临床,2014,30(1):70-73.
[5]张立英.四联疗法治疗幽门螺旋杆菌感染84例疗效观察[J].中国医学创新,2011,08(12):25-26.
[6]史新荣.莫沙比联合标准四联疗法治疗幽门螺旋菌阳性功能性消耗不良的效果观察[J].中国医药指南,2013,(16):605-606.
[7]张万岱,胡伏莲,萧树东,徐智民.中国自然人群幽门螺杆菌感染的流行病学调查[J].现代消化及介入诊疗,2010,05:265-270.
[8]胡伏莲.重视幽门螺杆菌感染处理中的临床问题[J].中国实用内科杂志,2008,09:713-715.
[9]刘文忠,谢勇,成虹,吕农华,胡伏莲,张万岱,周丽雅,陈烨,曾志荣,王崇文,萧树东,潘国宗,胡品津.第四次全国幽门螺杆菌感染处理共识报告[J].现代消化及介入诊疗,2012,06:358-363
[2]于凌琪.幽门螺旋杆菌的研究进展[J].中国慢性病预防与控制,2010,02:218-219.
[3]胡伏莲.幽门螺杆菌感染与上胃肠道疾病[J].临床内科杂志,2003,02:57-59.
[4]王晶桐,林珊珊,刘玉兰等.不同方案根除幽门螺旋杆菌效果对比分析[J]中国综合临床,2014,30(1):70-73.
[5]张立英.四联疗法治疗幽门螺旋杆菌感染84例疗效观察[J].中国医学创新,2011,08(12):25-26.
[6]史新荣.莫沙比联合标准四联疗法治疗幽门螺旋菌阳性功能性消耗不良的效果观察[J].中国医药指南,2013,(16):605-606.
[7]张万岱,胡伏莲,萧树东,徐智民.中国自然人群幽门螺杆菌感染的流行病学调查[J].现代消化及介入诊疗,2010,05:265-270.
[8]胡伏莲.重视幽门螺杆菌感染处理中的临床问题[J].中国实用内科杂志,2008,09:713-715.
[9]刘文忠,谢勇,成虹,吕农华,胡伏莲,张万岱,周丽雅,陈烨,曾志荣,王崇文,萧树东,潘国宗,胡品津.第四次全国幽门螺杆菌感染处理共识报告[J].现代消化及介入诊疗,2012,06:358-363